Kornimate/medical-research-clean huggingface dataset:
pet/ct imaging of small cell lung cancer using 89zr-dfo-sc16.56

Conditions: Small Cell Lung Cancer; Small Cell Lung Carcinoma

Summary: the purpose of this study is to look at how safe 89zr-dfo-sc16.56 is, and how it is processed by the body in people with small cell lung cancer.


Eligibility criteria:
inclusion criteria: * signed, informed consent * age 18 or more years * histologically confirmed, sclc, (newly diagnosed or recurrent); small cell carcinoma of unknown or non-lung origin; or other types of neuroendocrine tumor or * histologically confirmed prostate cancer, with suspected or confirmed nepc based upon clinical assays obtained prior to the trial * at least one tumor lesion on ct or mri \>/= 2 cm ° for the prostate cancer patient cohort with only bone metastases, a recent pet scan (fdg or psma-targeted) that shows tracer-avid osseous metastases, a recent mri that shows new osseous metastases, or a bone scan that shows new osseous metastases. the scans should have been obtained in the last 8 weeks. * ecog performance status 0 to 2 * negative serum pregnancy test within 2 weeks of 89zr- dfo-sc16.56 or women of child-bearing potential * adequate organ function as assessed by * absolute neutrophil count (anc) \>/= 1,500 mm\^8 * hemoglobin \>/= 8.0 g/dl * platelet count \>/= 75,000/mm\^3 * bilirubin \</= 1.5 x uln (upper limit of the norm) * ast (got) \</= 3.0 x uln (when no liver metastases are present) * ast (got) \</= 5.0 x uln (when liver metastases are present) * alt (got) \</= 3.0 x uln (when no liver metastases are present) * alt (got) \</= 5.0 x uln (when no liver metastases are present) * creatinine \</= 1.5 x uln * available archival tumor biopsy material suitable for dll3 ihc. archival tissue is not required to have been collected within a specific time frame relative to imaging * for the prostate cancer patient cohort, as an alternative if archival tissue is not available, patients must be willing to undergo pet/ct guided biopsy\*\* as described in section 9.3. 1. patients with sclc will be the primary study population, however patients with other types of neuroendocrine tumors may be included at the pi's discretion. 2. criterion is intended to demonstrate presence of imageable disease. a low-dose ct (e.g. from a pet/ct scan) may be used at pi's discretion 3. while willingness to undergo the biopsy is required if archival tissue is not available, pet/ct guided biopsy is not a mandatory study assessment. as described in section 9.3, the guided biopsy may be waived at the discretion of the principal investigator if the dll3 pet/ct reveals no sites of dll3 tracer-avid tumor or if the principal investigator deems it is not in the best interest of the patient, according to best clinical judgement. exclusion criteria: * history of anaphylactic reaction to humanize or human antibodies * pregnant or breast feeding * psychiatric illness that would interfere with compliance with the study procedures * inability to undergo pet scan due to weight limit

Keywords: small cell lung cancer small cell lung carcinoma 89zr-dfo-sc16.56 19-292 memorial sloan kettering cancer center
bgj398 for patients with tumors with fgfr genetic alterations

Conditions: Solid Tumor; Hematologic Malignancies

Summary: the purpose of this signal seeking study was to determine whether treatment with bgj398 demonstrates sufficient efficacy in select fgfr pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.


Eligibility criteria:
inclusion criteria: patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis of urothelial cell carcinoma, cholangiocarcinoma, endometrial cancer, and glioblastoma multiforme) or hematologic malignancies and is in need of treatment because of progression or relapse. patient's tumor has been evaluated and pre-identified as having a tumor with a fgfr genetic alteration. the qualifying alteration must be assessed and reported by a clia-certified laboratory. patient must have received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission. patient must have progressive and measurable disease per recist 1.1. or other appropriate hematological response criteria. patient has an eastern cooperative oncology group (ecog) performance status ≤ 1 exclusion criteria: patient has received prior treatment with bgj398 patients with central nervous system (cns) metastasis or leptomeningeal carcinomatosis patient has received chemotherapy or other anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-c) prior to starting study drug. patients with acute or chronic pancreatitis patients with impaired cardiac function or clinically significant cardiac diseases history and/or current evidence of extensive tissue calcification use of medications that increase serum levels of phosphorus and/or calcium current evidence of corneal or retinal disorder/keratopathy history and/or current evidence of renal or endocrine alterations of calcium/phosphate homeostasis patients with another primary malignancy within 3 years prior to starting study treatment, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix

Keywords: solid tumor malignancy hematologic malignancy mutation translocations amplifications, fusions signature fgfr ligand bgj398
the influence of genetic predisposition on outcome after catheter ablation of atrial fibrillation.

Conditions: Atrial Fibrillation

Summary: catheter ablation is an established standard therapy in interventional treatment of atrial fibrillation.the trial investigates the influence of genetic risk for the recurrence of atrial fibrillation after catheter ablation.

catheter ablation is an established standard therapy in interventional treatment of atrial fibrillation. electric isolation of the pulmonary veins, from which atrial fibrillation is originating in most patients, is cornerstone of all atrial fibrillation patients. the most common cause for af recurrence is still incomplete isolation of the pulmonary veins, on the other hand, only 80% of paroxysmal and 60 % of persistent patients can successfully be cured from atrial fibrillation (despite of isolated pulmonary veins after multiple ablation procedures). by now, non-procedure related predictive risk factors, resulting in recurrence of atrial fibrillation after catheter ablation, are only partially identified, such as obesity, hypertension and sleep apnea. in the past year several genetic risk alleles were identified, which are associated with atrial fibrillation. by now the relation between genetic risk, which is determined for every patient by its specific genotype and the outcome of catheter ablation in paroxysmal and persistent atrial fibrillation has not yet been investigated. the aim is to investigate the influence of genetic risk for the recurrence of atrial fibrillation after catheter ablation.

Eligibility criteria:
inclusion criteria: * patients planned for primary ablation due to paroxysmale or persistent atrial fibrillation * written informed consent exclusion criteria: * patients under 18 years of age or patients not able to give informed consent * prior left atrial ablation
radiofrequency ablation for warthin's tumor

Conditions: Radiofrequency Ablation

Summary: this study is a safety and feasibility study to determine if ultrasound guided radiofrequency ablation of parotid warthin's tumor under local anesthesia is a safe and effective procedure compared to parotidectomy while using less resources.

radiofrequency ablation is minimally invasive and is used in benign disease, including thyroid nodules, head and neck nodules, and vascular malformations, as well as some malignant tumors. for patients unable to or unwilling to undergo surgical resection, real-time ultrasound guided radiofrequency ablation for parotid warthin's tumor would be a further option besides observation alone. twenty patients with warthin's tumor from the ent head and neck surgery out-patient clinic at prince of wales hospital will be recruited. the patient will first be asked if they wanted intervention for their condition of warthin's tumor. parotidectomy will first be offered. if the patient opted for intervention but declines parotidectomy, then ultrasound guided rfa will be offered. the 2019 - 2020 parotidectomy for warthin's tumor internal audit will be used as a historical comparison to the ultrasound guided rfa group.

Eligibility criteria:
inclusion criteria: 1. 18 years and older 2. ultrasound scan findings: 1. tumor size 2cm-5cm 2. tumor located in superficial lobe of parotid gland with epicenter in parotid tail 3. tumor is clinically palpable tumor 4. symptomatic disease with facial asymmetry and cosmetic concerns 5. diagnosis confirmed by fine needle aspiration x 2 1. warthin's tumor 2. no other parotid pathologies exclusion criteria: 1. facial nerve palsy 2. history of parotid surgery 3. history or symptoms of sialolithiasis 4. medical facial skin conditions 5. bleeding tendencies 6. pregnancy 7. pacemaker
evaluation of inrs with bcsk in children with spastic bilateral cerebral palsy: a randomized controlled trial.

Conditions: Spastic Diplegia Cerebral Palsy

Summary: a randomized control trial investigating "biomechanical correction of the spine according to kozyavkin" (bcsk) which is a part of the treatment concept "intensive neurophysiological rehabilitation system" (inrs). bcsk is used with the aims to reduce muscle tone and improve gross and fine motor function in children with spastic bilateral cerebral palsy.

the study is a collaboration between the international clinic of rehabilitation (icr) in ukraine and the karolinska institute (ki) in sweden. the intervention and the assessments are performed at icr. the primary outcome measure, evaluation of gross motor function with the test gmfm 66 is filmed and the recordings are transferred to ki together with all assessment data. ki are responsible for study research design and collects, analyzes and processes all data. it is a double blinded study. only two persons will know to which group the subject belongs, the person performing the randomization process in sweden and the doctor performing the spinal corrections. there are two aims of the study; 1. to evaluate the effect of "biomechanical correction of the spine" (bcsk) in children with spastic bilateral cerebral palsy. 2. to evaluate the effect of "intensive neurophysiological rehabilitation system" (inrs) in children with spastic bilateral cerebral palsy.

Eligibility criteria:
inclusion criteria: * children with spastic bilateral form of cerebral palsy according surveillance of cerebral palsy in europe (scpe) criteria * gmfcs levels ii-iv * the children should not have received previous inrs treatment exclusion criteria: * other forms of cerebral palsy * severe epileptic syndrome * severe mental retardation * orthopedic surgery within the last year

Keywords: cerebral palsy, spastic, diplegic, children, intervention study, manipulation, spinal randomized controlled trial
study of difluprednate ophthalmic emulsion in postoperative inflammation

Conditions: Inflammation

Summary: the purpose of this phase 3 study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of postoperative inflammation.

the objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion in patients with intraocular postoperative inflammation.

Eligibility criteria:
inclusion criteria: * patients who have undergone cataract surgery, vitreous surgery or both (including patients who have undergone iol insertion surgery at the same time) * patients showing an anterior chamber cell score of not less than "2" at a day after surgery * patients aged 20 years or over, irrespective of genders (it is eligible for enrollment when patients' age attains the criterion on the day of consent obtainment) exclusion criteria: * patients who took systemic administration of corticosteroids or immunosuppressive agents, or used ophthalmic ointments of corticosteroids within 1 week before instillation of the investigational drugs; * patients who underwent local injection of corticosteroids in the eyes before instillation of the investigational drugs; (patients who used aqueous preparations within 1 week or patient who used depot preparations within 2 weeks were excluded) * patients who took systemic administration of non-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 3 days before instillation of the investigational drugs; * patients who instilled of corticosteroids, no-steroidal antiinflammatory agents or antiinflammatory enzyme preparations within 24 hours before the pre-instillation observation (a day after surgery); * patients who underwent perioperative and/or postoperative intravitreous injection of corticosteroids; * patients who underwent sub-conjunctival injection or sub-tenon capsule injection of corticosteroids; * patients who have intraocular hemorrhage with a degree that may affect the postoperative evaluations; * patients who underwent gas tamponade at the surgery; * patients with endogenous uveitis; * patients having corneal epithelial detachment or corneal ulcer in the target eye; * patients who are suspected of having viral, bacterial or mycotic keratoconjunctival disorders in the target or opposite eye; * patients with glaucoma or ocular hypertension, or those with past history of iop increased due to instillation of corticosteroids, or those whose iop has been controlled by use of ophthalmic antihypertensive agents; * patients showing iop not less than 25 mmhg a day after surgery; * patients who have allergy to corticosteroid drugs; * patients who are required to wear contact lens during the study period; * patients who are scheduled to undergo surgery of the opposite eye during the study period; * patients who are pregnant or may be pregnant or lactating; * patients who have participated in other clinical studies within 3 months.
safety and efficacy of nalmefene in patients with alcohol dependence

Conditions: Alcohol Dependence

Summary: the purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.

alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. this study is planned to evaluate the long-term safety and tolerability as well as to evaluate the efficacy of as needed use of 18.06 mg nalmefene in patients with alcohol dependence.

Eligibility criteria:
inclusion criteria: in- and outpatients who: * had a primary diagnosis of alcohol dependence according to diagnostic and statistical manual of mental disorders - text revision (dsm-iv-tr) criteria * had had ≥6 heavy drinking days (hdds) in the 4 weeks preceding the screening visit exclusion criteria: the patient: * had a severe psychiatric disorder or an antisocial personality disorder * had risk of suicide evaluated by the suicidality module of the mini-international neuropsychiatric interview (mini) * had a history of delirium tremens or alcohol withdrawal seizures * reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists * was pregnant or breast-feeding other protocol-defined inclusion and exclusion criteria may apply.

Keywords: pharmacologic actions alcohol-related disorders alcoholism mental disorders central nervous system agents
study of the penumbra coil 400 system to treat aneurysm

Conditions: Intracranial Aneurysms; Peripheral Aneurysms

Summary: this is a prospective, multi-center study of patients with intracranial or peripheral aneurysms who are treated by the pc 400 system. the primary objective is to gather post market data on the penumbra coil 400 (pc 400) system in the acute treatment of intracranial and peripheral aneurysms. approximately 2,000 patients with intracranial or peripheral aneurysms treated by the pc 400 system at up to 100 centers will be enrolled. data for each patient are collected up to discharge or 3 days post-procedure, whichever occurs sooner. long term follow-up to one year will be conducted in accordance to the standard of care at each participating hospital.


Eligibility criteria:
inclusion criteria: patients enrolled in this study must be those treated according to the cleared indication for the pc 400 system which is for the endovascular embolization of: * intracranial aneurysms * other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae * arterial and venous embolizations in the peripheral vasculature exclusion criteria: * patients in whom endovascular embolization therapies other than penumbra coils are used will be excluded from this study. however, adjunctive use of balloon and stent are acceptable.

Keywords: intracranial aneurysms peripheral aneurysms acute treatment pc 400 system packing density
urban environmental exposures and childhood cancer

Conditions: Brain Cancer; Acute Lymphoblastic Leukemia

Summary: the environmental protection agency has recognized that organophosphorus pesticides require close regulation and continued monitoring for human health effects and some (e.g chlorpyrifos) have been phased-out from the consumer market due to the special risk that it posed for children. there is growing evidence in support of the association between pesticide exposure and childhood leukemia. studies of pesticides and their association with childhood cancer have been limited by study designs, self-reporting and lack of biological measurements. while several large studies in california found little evidence of an association between agricultural pesticide use and childhood leukemia, these results are in contrast with the associations observed with household exposures to pesticides. the real association may depend on timing of exposure, type of pesticide, dose and pathway of exposure. furthermore, some persons may be more susceptible to the effects of specific pesticides due to inherited mutations in their detoxification pathways. we are conducting a pilot study to test the hypothesis that environmental exposure to pesticides in pregnancy or during the neonatal period, together with genetic susceptibility may lead to childhood all or brain cancer. the study is a multicenter, case-control study, based on collaboration between clinical researchers and basic science research to evaluate the risk for childhood cancer in relation to measured levels of pesticides (and their metabolites) and genetic polymorphisms. biomarkers will be used to examine the risks of chronic low-dose exposures, and to characterize relationships between specific pesticides, childhood cancer and genetic susceptibility. hypothesis: interaction between environmental factors (pesticides) and maternal or child genetic polymorphisms may lead to childhood cancer.


Eligibility criteria:
inclusion criteria: * only newly diagnosed cases of all and brain cancers (i.e. diagnosed within the previous 12 months) under the age of 18 years are eligible for this study. these will include live born infants at term or born prematurely, and any cases we are able to ascertain from pediatric hematology records. * healthy controls of similar age will be recruited. * the children must have a parent available to be interviewed who speaks english or spanish well enough to understand the questionnaire. exclusion criteria: * subjects with a diagnosis of down syndrome or other chromosomal disorder, single gene disorder, or recognized multi-organ syndrome will be excluded. * non-residents of maryland, the district of columbia, and virginia will be excluded; this will avoid the inclusion of out-of-state case families who traveled a long distance for clinical care, where control sampling would be problematic.

Keywords: childhood brain cancer childhood acute lymphoblastic leukemia
the value of pet imaging targeting granzyme b in predicting efficacy and prognosis in t-nk cell lymphoma

Conditions: T-NK Cell Lymphoma

Summary: the study on the value of pet imaging targeting granzyme b in predicting the efficacy and prognosis of t-nk cell lymphoma.

the investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. all participants will undergo 68ga-grazytracer pet at baseline and after one course of immunotherapy.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years, regardless of gender. 2. histopathologically confirmed diagnosis of t-nk cell lymphoma. 3. newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy. 4. availability of complete clinicopathological and follow-up data. 5. signed and dated informed consent form. exclusion criteria: 1. patients who have previously received anti-tumor therapy. 2. patients with a history of other malignancies. 3. incomplete clinical information or imaging data. 4. concurrent other malignant tumors. 5. patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction. 6. poor compliance.

Keywords: pet/ct granzyme b immunotherapy
assessment of dafilon® suture material for skin closure

Conditions: Laceration of Skin; Injury Skin

Summary: in this non-interventional study (nis) a polyamide non-absorbable suture (dafilon®) will be evaluated for skin closure in adult and pediatric patients. the aim of the study is to collect clinical data on the performance of dafilon® for skin closure. the results of this study will generate further clinical evidence for the use and the benefit of a non-absorbable surgical suture material produced from polyamide. furthermore, the proactive collection of clinical data for dafilon® suture will support the maintenance of the suture material on the market, so that in the future other patients can receive the suture material for skin closure.


Eligibility criteria:
inclusion: * written informed consent is available * patients undergoing skin closure with dafilon® * small linear minimally contaminated incision/laceration in the trunk or extremities exclusion: * emergency surgery * pregnancy * facial lacerations or incisions * visible dirt in the wounds * nonlinear shape * patient taking medication that might affect wound healing * patient with hypersensitivity or allergy to the suture material

Keywords: non-absorbable suture skin closure surgical site infection wound dehiscence
effectiveness of mat pilates and aerobic training on fatigue and depression

Conditions: Post Partum Depression

Summary: the aim is to see fatigue and depression levels in postpartum females and to evaluate ho two well-known exercises, mat pilates and aerobic training can help to reduce the fatigue levels in postpartum females

the aim is to see fatigue and depression levels in postpartum females and to evaluate ho two well-known exercises, mat pilates and aerobic training can help to reduce the fatigue levels in postpartum females. in this study, the researcher will also compare the effects of mat pilates and aerobic training on fatigue and depression levels among postpartum females.

Eligibility criteria:
inclusion criteria: * vaginal delivery * singleton pregnancy exclusion criteria: * caesarean delivery * vacuum-assisted delivery * sexually transmitted diseases * menopause females * any condition regarding obstetrics \& gynecology * any physical or mental illness

Keywords: depression fatigue low intensity aerobic training mat-pilates